HTFL at a glance
Heartflow, Inc. (HTFL, SEC CIK 1464521) filed its latest 10-K annual report on March 18, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as November 19, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Heartflow, Inc. (HTFL) reported revenue of $176.0 million (up 39.9% from FY2024) and a net loss of $116.8 million. Diluted EPS was -$3.17.
- As of September 30, 2026, 26 institutional investment managers tracked by SignalX reported holding Heartflow, Inc. (HTFL) shares worth $1.4 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Rogers Campbell on November 17, 2026 of 5,654 shares at $46.39 per share.
- In the last 90 days, HTFL insiders reported 0 open-market purchases ($0) and 22 open-market sales ($16.4M) on Form 4, a net sale of $16.4M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $176.0M
- +39.9% vs prior year
- Insiders · 90 days
- 0 buys · 22 sells
- Net −$16.4M
- 13F holders
- 26 funds
- $1.4B · −2 vs prior quarter
- Latest 8-K
- Nov 12, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material changes from the March 18, 2026 Form 10-K risk factors
- Regulatory and compliance exposure: SEC and healthcare requirements could adversely affect operations
- Operational risk: Additional unknown or currently immaterial risks could harm business performance
- Market risk: Risk factors could adversely affect Heartflow’s common-stock price
Management Discussion & Analysis
- Q3 revenue $72.9M, up 57% YoY from $46.3M, driven by 89% revenue-case growth
- Gross margin 84% vs 77% YoY, with Plaque Analysis and AI productivity benefits
- Plaque Analysis, strengthened by CPT 75577 reimbursement, drove adoption; PCI Navigator phased launch began April 2026
- Cash, equivalents and investments $253.0M; nine-month operating cash use $38.4M vs $43.4M
- Outlook: continued losses, production hiring and training, higher R&D and public-company costs; liquidity expected for at least 12 months
AI summary of the HTFL 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Heartflow announced financial results for the quarter ended September 30, 2026
- Exhibit 99.1 contains the detailed earnings release and operating performance information
Item EX-99.1: Item EX-99.1
- Q3 revenue $72.9M, up 57% YoY, with U.S. revenue up 60% to $67.9M
- Gross margin expanded to 83.6% from 76.5%, supported by higher case volumes and AI-driven productivity
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results covered quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1 contains the financial results
Item EX-99.1: Item EX-99.1
- Q2 revenue $64.1M, up 48% YoY, led by U.S. revenue growth of 51% to $59.6M
- Gross margin expanded to 83.0% from 75.5%, supported by higher case volumes and AI-driven production efficiency
Item 5.07: Submission of Matters to a Vote of Security Holders
- Julie A. Cullivan and John C.M. Farquhar elected as Class I directors through the 2029 annual meeting
- Director votes included 11,550,151 broker non-votes, limiting participation in board elections
AI summaries of HTFL 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for HTFL
Don't miss the next HTFL filing
- Alerts as it files. A push when HTFL files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut HTFL, by share count.
- Ask anything. An AI agent that reads every HTFL filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Rogers Campbell | M | Nov 17, 2026 | 5,101 | - |
| Rogers Campbell | M | Nov 17, 2026 | 5,101 | $2.22 |
| Rogers Campbell | M | Nov 17, 2026 | 12,328 | - |
| Rogers Campbell | Sell | Nov 17, 2026 | 5,654 | $46.39 |
| Rogers Campbell | Sell | Nov 17, 2026 | 6,503 | $46.39 |
| Rogers Campbell | Sell | Nov 17, 2026 | 24,188 | $46.39 |
| Rogers Campbell | M | Nov 17, 2026 | 12,328 | $8.33 |
| Farquhar John C.M. | Sell | Nov 10, 2026 | 38,900 | $55.74 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $125.8M | $176.0M |
| Gross Profit | - | $94.4M | $135.2M |
| Operating Income | - | -$61.2M | -$64.1M |
| Net Income | - | -$96.4M | -$116.8M |
| Gross Margin | - | 75.1% | 76.8% |
| Op. Margin | - | -48.7% | -36.4% |
| Net Margin | - | -76.6% | -66.3% |
| Balance Sheet | |||
| Total Assets | - | $118.7M | $359.5M |
| Equity | -$777.6M | -$859.5M | $300.6M |
| ROE | - | 11.2% | -38.8% |
| Per Share | |||
| EPS | - | $-17.98 | $-3.17 |
| Cash Flow | |||
| Operating CF | - | -$69.0M | -$54.0M |
| CapEx | $6.1M | $4.4M | $5.0M |
Source: XBRL data in Heartflow, Inc. (HTFL)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate HTFL share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 26 | $1.38B |
| Q2 2026 | 28 | $820.5M |
| Q1 2026 | 22 | $439.3M |
| Q4 2025 | 18 | $350.5M |
| Q3 2025 | 17 | $357.1M |
- D.E. Shaw & Co+2.10M (+24210%)
- BlackRock+843.2K (+16%)
- Renaissance Technologies LLC+611.2K (+160%)
- Vanguard Capital Management LLC+562.5K (+20%)
- Two Sigma Investments+426.8K (+5989%)
- Citadel Advisors LLC−512.6K (-64%)
- BNY Mellon−348.2K (-53%)
- Bank of America Corp−230.8K (-41%)
- AQR Capital Management−147.9K (-49%)
- Wells Fargo & Co−88.9K (-75%)
- FMR LLC (Fidelity)−4.82M
- Allstate−29.1K
- Blackstone Group−7.7K
- Fifth Third Bancorp−645
Source: 13F-HR filings on SEC EDGAR (aggregated from 111 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
HTFL filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 19, 2026 | - | - | - |
| 8-K | Nov 12, 2026 | - | Analysis | - |
| 10-Q | Nov 12, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Nov 10, 2026 | - | - | - |
| 4 | Nov 10, 2026 | - | - | - |
| 4 | Nov 10, 2026 | - | - | - |
| 4 | Nov 10, 2026 | - | - | - |
| 4 | Oct 26, 2026 | - | - | - |
| 4 | Oct 14, 2026 | - | - | - |
| 4 | Sep 21, 2026 | - | - | - |
| 4 | Sep 18, 2026 | - | - | - |
| 4 | Sep 15, 2026 | - | - | - |
| 4 | Sep 14, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 19, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 8-K | Aug 13, 2026 | - | Analysis | - |
| 10-Q | Aug 13, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 10, 2026 | - | - | - |
| 4 | Aug 10, 2026 | - | - | - |
| 4 | Aug 10, 2026 | - | - | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
HTFL SEC filings: frequently asked questions
Are HTFL insiders buying or selling?
In the last 90 days, Heartflow, Inc. (HTFL) officers, directors and 10% owners reported no open-market purchases and 22 open-market sales worth $16.4 million by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold HTFL stock?
As of September 30, 2026, the largest Heartflow, Inc. (HTFL) holders among the 13F filers tracked by SignalX were BlackRock ($300.5 million), Vanguard Portfolio Management LLC ($185.0 million), Vanguard Capital Management LLC ($165.0 million), Invesco Ltd ($134.0 million), D.E. Shaw & Co ($105.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was HTFL's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Heartflow, Inc. (HTFL) reported revenue of $176.0 million (up 39.9% from FY2024) and a net loss of $116.8 million. Diluted EPS was -$3.17. The figures come from the XBRL data in the 10-K.
What did HTFL report in its latest 8-K?
Heartflow, Inc. (HTFL) filed an 8-K on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Heartflow announced financial results for the quarter ended September 30, 2026.
What are the latest HTFL SEC filings?
Heartflow, Inc. (HTFL) filed its latest 10-K annual report on March 18, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on November 19, 2026.
What is HTFL's SEC CIK number?
Heartflow, Inc. (HTFL)'s SEC Central Index Key (CIK) is 1464521. EDGAR lists every HTFL filing under that number.
Ask anything about HTFL
The research agent reads HTFL's filings, financials, insider trades and 13F holders, then answers with sources.